Mauro Turrini

Dr. Mauro Turrini

Division of Hematolog, Department of Medicine, Valduce Hospital Como, Italy
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2008 in Leukemia Research
Verified
Journal Article
Closed access
LMLaura Marbello
Laura Marbello
FRFrancesca Ricci
Francesca Ricci
ANAnna Maria Nosari
Anna Maria Nosari
MTMauro Turrini
Mauro Turrini
GNGuido Nador
Guido Nador
EMEnrica Morra
Enrica Morra

1 November 2007 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
ECEmanuele Cereda
Emanuele Cereda
MTMauro Turrini
Mauro Turrini
DCDenis Ciapanna
Denis Ciapanna
LMLaura Marbello
Laura Marbello
APAngelo Pietrobelli
Angelo Pietrobelli
ECEttore Corradi
Ettore Corradi

11 January 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
CVCarlo Visco
Carlo Visco
LMLuigi Marcheselli
Luigi Marcheselli
Roberto MinaRoberto Mina
Roberto Mina
MSMarianna Sassone
Marianna Sassone
AGAnna Guidetti
Anna Guidetti
FMFrancesco Merli
Francesco Merli
Lymphoma represents a heterogeneous hematological malignancy (HM), which is characterized by severe immunosuppression. Patients diagnosed of coronavirus disease 2019 (COVID-19) during the course of HM have been described to have poor outcome, with only few reports specifically addressing lymphoma patients. Here, we investigated the clinical behavior and clinical parameters of a large multicenter cohort of adult patients with different lymphoma subtypes, with the aim of identifying predictors of death. The study included 856 patients, of whom 619 were enrolled prospectively in a 1-year frame and were followed-up for a median of 66 days (range 1-395). Patients were managed as outpatient (not-admitted cohort, n = 388) or required hospitalization (n = 468), and median age was 63 years (range 19-94). Overall, the 30- and 100-days mortality was 13% (95% confidence interval (CI), 11% to 15%) and 23% (95% CI, 20% to 27%), respectively. Antilymphoma treatment, including anti-CD20 containing regimens, did not impact survival. Patients with Hodgkin’s lymphoma had the more favorable survival, but this was partly related to significantly younger age. The time interval between lymphoma diagnosis and COVID-19 was inversely related to mortality. Multivariable analysis recognized 4 easy-to-use factors (age, gender, lymphocyte, and platelet count) that were associated with risk of death, both in the admitted and in the not-admitted cohort (HR 3.79 and 8.85 for the intermediate- and high-risk group, respectively). Overall, our study shows that patients should not be deprived of the best available treatment of their underlying disease and indicates which patients are at higher risk of death. This study was registered with ClinicalTrials.gov, NCT04352556.

7 April 2021 in Personalized Medicine
Verified
Journal Article
Open access
Christine NardiniChristine Nardini
Christine Nardini
VOVenet Osmani
Venet Osmani
PCPaola G Cormio
Paola G Cormio
AFAndrea Frosini
Andrea Frosini
MTMauro Turrini
Mauro Turrini
GDGianni D’errico
Gianni D’errico
Personalized medicine (PM) moves at the same pace of data and technology and calls for important changes in healthcare. New players are participating, providing impulse to PM. We review the concept...

1 November 2010 in Neoplasia
Verified
Journal Article
Open access
PDF file
MBMatteo Brioschi
Matteo Brioschi
JFJohn Fischer
John Fischer
RCRoberto Cairoli
Roberto Cairoli
SRStefano Rossetti
Stefano Rossetti
LPLaura Pezzetti
Laura Pezzetti
ABAlessandro Beghini
Alessandro Beghini
Neoplasia publishes the results of novel investigations in all areas of oncology research.

1 December 2012 in Neoplasia
Verified
Journal Article
Open access
ABAlessandro Beghini
Alessandro Beghini
FCFrancesca Corlazzoli
Francesca Corlazzoli
LGLuca Del Giacco
Luca Del Giacco
MRMatteo Re
Matteo Re
FLFrancesca Lazzaroni
Francesca Lazzaroni
RCRoberto Cairoli
Roberto Cairoli
Acute myeloid leukemia (AML) is a genetically heterogeneous clonal disorder characterized by two molecularly distinct self-renewing leukemic stem cell (LSC) populations most closely related to normal progenitors and organized as a hierarchy. A requirement for WNT/β-catenin signaling in the pathogenesis of AML has recently been suggested by a mouse model. However, its relationship to a specific molecular function promoting retention of self-renewing leukemia-initiating cells (LICs) in human remains elusive. To identify transcriptional programs involved in the maintenance of a self-renewing state in LICs, we performed the expression profiling in normal (n = 10) and leukemic (n = 33) human long-term reconstituting AC133(+) cells, which represent an expanded cell population in most AML patients. This study reveals the ligand-dependent WNT pathway activation in AC133(bright) AML cells and shows a diffuse expression and release of WNT10B, a hematopoietic stem cell regenerative-associated molecule. The establishment of a primary AC133(+) AML cell culture (A46) demonstrated that leukemia cells synthesize and secrete WNT ligands, increasing the levels of dephosphorylated β-catenin in vivo. We tested the LSC functional activity in AC133(+) cells and found significant levels of engraftment upon transplantation of A46 cells into irradiated Rag2(-/-)γc(-/-) mice. Owing to the link between hematopoietic regeneration and developmental signaling, we transplanted A46 cells into developing zebrafish. This system revealed the formation of ectopic structures by activating dorsal organizer markers that act downstream of the WNT pathway. In conclusion, our findings suggest that AC133(bright) LSCs are promoted by misappropriating homeostatic WNT programs that control hematopoietic regeneration.